SUPERNUS PHARMACEUTICALS, INC. Selling, General and Administrative Expense
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Selling, General and Administrative Expense of $133.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-03
- SUPERNUS PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $133.64M, a 42.85% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $125.17M, a 39.17% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $122.39M, a 54.13% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $179.68M, a 157.59% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2025 was $485.56M, a 50.99% increase from fiscal 2024.
- SUPERNUS PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2024 was $321.58M, a 4.39% decline from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2023 was $336.36M, a 10.83% decline from fiscal 2022.
- SUPERNUS PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2022 was $377.22M, a 23.78% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $133.64M 10-Q · filed 2026-08-03 | $258.81M 10-Q · filed 2026-08-03 | $381.20M derived: sum of 3 quarters · filed 2026-08-03 | $560.88M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2026-03-31 | $125.17M 10-Q · filed 2026-05-05 | $247.56M derived: sum of 2 quarters · filed 2026-05-05 | $427.24M derived: sum of 3 quarters · filed 2026-05-05 | $520.79M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-12-31 | $122.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $302.07M derived: sum of 2 quarters · filed 2026-03-02 | $395.62M derived: sum of 3 quarters · filed 2026-08-03 | $485.56M 10-K · filed 2026-03-02 | ||||
| 2025-09-30 | $179.68M 10-Q · filed 2025-11-06 | $273.23M derived: sum of 2 quarters · filed 2026-08-03 | $363.17M 10-Q · filed 2025-11-06 | $442.58M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-06-30 | $93.55M 10-Q · filed 2026-08-03 | $183.50M 10-Q · filed 2026-08-03 | $262.90M derived: sum of 3 quarters · filed 2026-08-03 | $332.66M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-03-31 | $89.94M 10-Q · filed 2026-05-05 | $169.35M derived: sum of 2 quarters · filed 2026-05-05 | $239.11M derived: sum of 3 quarters · filed 2026-05-05 | $325.01M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $79.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $149.16M derived: sum of 2 quarters · filed 2026-03-02 | $235.07M derived: sum of 3 quarters · filed 2026-03-02 | $321.58M 10-K · filed 2026-03-02 | ||||
| 2024-09-30 | $69.75M 10-Q · filed 2025-11-06 | $155.66M derived: sum of 2 quarters · filed 2025-11-06 | $242.17M 10-Q · filed 2025-11-06 | $323.45M derived: sum of 4 quarters · filed 2026-03-02 | ||||
| 2024-06-30 | $85.90M 10-Q · filed 2025-08-05 | $172.42M 10-Q · filed 2025-08-05 | $253.70M derived: sum of 3 quarters · filed 2026-03-02 | $336.40M derived: sum of 4 quarters · filed 2026-03-02 | ||||
| 2024-03-31 | $86.52M 10-Q · filed 2025-05-06 | $167.80M derived: sum of 2 quarters · filed 2026-03-02 | $250.50M derived: sum of 3 quarters · filed 2026-03-02 | $337.28M derived: sum of 4 quarters · filed 2026-03-02 | ||||
| 2023-12-31 | $81.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $163.98M derived: sum of 2 quarters · filed 2026-03-02 | $250.76M derived: sum of 3 quarters · filed 2026-03-02 | $336.36M 10-K · filed 2026-03-02 | ||||
| 2023-09-30 | $82.70M 10-Q · filed 2024-11-04 | $169.48M derived: sum of 2 quarters · filed 2024-11-04 | $255.08M 10-Q · filed 2024-11-04 | $329.05M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | $86.78M 10-Q · filed 2024-08-06 | $172.38M 10-Q · filed 2024-08-06 | $246.35M derived: sum of 3 quarters · filed 2025-02-25 | $358.67M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | $85.60M 10-Q · filed 2024-05-08 | $159.57M derived: sum of 2 quarters · filed 2025-02-25 | $271.88M derived: sum of 3 quarters · filed 2025-02-25 | $372.36M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | $73.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $186.29M derived: sum of 2 quarters · filed 2025-02-25 | $286.76M derived: sum of 3 quarters · filed 2025-02-25 | $377.22M 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $112.31M 10-Q · filed 2023-11-08 | $212.79M derived: sum of 2 quarters · filed 2023-11-08 | $303.25M 10-Q · filed 2023-11-08 | $404.98M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $100.48M 10-Q · filed 2023-08-08 | $190.94M 10-Q · filed 2023-08-08 | $292.67M derived: sum of 3 quarters · filed 2023-08-08 | $364.70M derived: sum of 4 quarters · filed 2023-08-08 | ||||
| 2022-03-31 | $90.46M 10-Q · filed 2023-05-09 | $192.19M derived: sum of 2 quarters · filed 2023-05-09 | $264.23M derived: sum of 3 quarters · filed 2023-05-09 | $333.76M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | $101.73M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $173.77M derived: sum of 2 quarters · filed 2023-03-09 | $243.30M derived: sum of 3 quarters · filed 2023-03-09 | $304.76M 10-K · filed 2023-03-09 | ||||
| 2021-09-30 | $72.03M 10-Q · filed 2022-11-09 | $141.57M derived: sum of 2 quarters · filed 2022-11-09 | $203.02M 10-Q · filed 2022-11-09 | $259.52M derived: sum of 4 quarters · filed 2023-03-09 | ||||
| 2021-06-30 | $69.53M 10-Q · filed 2022-08-08 | $130.99M 10-Q · filed 2022-08-08 | $187.49M derived: sum of 3 quarters · filed 2023-03-09 | $241.95M derived: sum of 4 quarters · filed 2023-03-09 | ||||
| 2021-03-31 | $61.46M 10-Q · filed 2022-05-12 | $117.96M derived: sum of 2 quarters · filed 2023-03-09 | $172.42M derived: sum of 3 quarters · filed 2023-03-09 | $220.52M derived: sum of 4 quarters · filed 2023-03-09 | ||||
| 2020-12-31 | $56.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $110.96M derived: sum of 2 quarters · filed 2023-03-09 | $159.06M derived: sum of 3 quarters · filed 2023-03-09 | $200.68M 10-K · filed 2023-03-09 | ||||
| 2020-09-30 | $54.46M 10-Q · filed 2021-11-05 | $54.66M 10-Q · filed 2020-11-06 | $102.56M derived: sum of 2 quarters · filed 2021-11-05 | $144.18M 10-Q · filed 2021-11-05 | $144.38M 10-Q · filed 2020-11-06 | $178.64M derived: sum of 4 quarters · filed 2022-04-13 | ||
| 2020-06-30 | $48.10M 10-Q · filed 2021-08-06 | $89.72M 10-Q · filed 2021-08-06 | $124.18M derived: sum of 3 quarters · filed 2022-04-13 | $163.52M derived: sum of 4 quarters · filed 2022-04-13 | ||||
| 2020-03-31 | $41.61M 10-Q · filed 2021-05-07 | $42.88M 10-Q · filed 2020-05-15 | $76.08M derived: sum of 2 quarters · filed 2022-04-13 | $115.42M derived: sum of 3 quarters · filed 2022-04-13 | $155.20M derived: sum of 4 quarters · filed 2022-04-13 | |||
| 2019-12-31 | $34.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-13 | $73.81M derived: sum of 2 quarters · filed 2022-04-13 | $113.58M derived: sum of 3 quarters · filed 2022-04-13 | $153.25M 10-K · filed 2022-04-13 | $158.43M 10-K · filed 2020-02-28 | |||
| 2019-09-30 | $39.34M 10-Q · filed 2020-11-06 | $40.65M 10-Q · filed 2019-11-08 | $79.12M derived: sum of 2 quarters · filed 2020-11-06 | $118.78M 10-Q · filed 2020-11-06 | $122.70M 10-Q · filed 2019-11-08 | $156.95M derived: sum of 4 quarters · filed 2021-03-08 | ||
| 2019-06-30 | $39.78M 10-Q · filed 2020-08-17 | $41.08M 10-Q · filed 2019-08-09 | $79.44M 10-Q · filed 2020-08-17 | $82.05M 10-Q · filed 2019-08-09 | $117.61M derived: sum of 3 quarters · filed 2021-03-08 | $158.50M derived: sum of 4 quarters · filed 2021-03-08 | ||
| 2019-03-31 | $40.97M 10-Q · filed 2020-05-15 | $77.83M derived: sum of 2 quarters · filed 2021-03-08 | $118.72M derived: sum of 3 quarters · filed 2021-03-08 | $158.82M derived: sum of 4 quarters · filed 2021-03-08 | ||||
| 2018-12-31 | $36.86M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $77.75M derived: sum of 2 quarters · filed 2021-03-08 | $117.85M derived: sum of 3 quarters · filed 2021-03-08 | $154.70M 10-K · filed 2021-03-08 | $159.89M 10-K · filed 2019-03-01 | |||
| 2018-09-30 | $40.89M 10-Q · filed 2019-11-08 | $80.99M derived: sum of 2 quarters · filed 2019-11-08 | $117.84M 10-Q · filed 2019-11-08 | $151.60M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-06-30 | $40.10M 10-Q · filed 2019-08-09 | $76.95M 10-Q · filed 2019-08-09 | $110.71M derived: sum of 3 quarters · filed 2020-02-28 | $151.53M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-03-31 | $36.85M 10-Q · filed 2019-05-10 | $70.61M derived: sum of 2 quarters · filed 2020-02-28 | $111.44M derived: sum of 3 quarters · filed 2020-02-28 | $146.52M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2017-12-31 | $33.76M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $74.59M derived: sum of 2 quarters · filed 2020-02-28 | $109.67M derived: sum of 3 quarters · filed 2020-02-28 | $137.91M 10-K · filed 2020-02-28 | ||||
| 2017-09-30 | $40.83M 10-Q · filed 2018-11-09 | $75.90M derived: sum of 2 quarters · filed 2018-11-09 | $104.14M 10-Q · filed 2018-11-09 | $133.19M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-06-30 | $35.08M 10-Q · filed 2018-08-09 | $63.32M 10-Q · filed 2018-08-09 | $92.37M derived: sum of 3 quarters · filed 2019-03-01 | $118.05M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-03-31 | $28.24M 10-Q · filed 2018-05-10 | $57.29M derived: sum of 2 quarters · filed 2019-03-01 | $82.97M derived: sum of 3 quarters · filed 2019-03-01 | $109.09M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2016-12-31 | $29.05M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $54.73M derived: sum of 2 quarters · filed 2019-03-01 | $80.85M derived: sum of 3 quarters · filed 2019-03-01 | $106.01M 10-K · filed 2019-03-01 | ||||
| 2016-09-30 | $25.68M 10-Q · filed 2017-11-09 | $51.80M derived: sum of 2 quarters · filed 2017-11-09 | $76.96M 10-Q · filed 2017-11-09 | $100.52M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-06-30 | $26.12M 10-Q · filed 2017-08-03 | $51.28M 10-Q · filed 2017-08-03 | $74.85M derived: sum of 3 quarters · filed 2018-03-01 | $97.75M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-03-31 | $25.16M 10-Q · filed 2017-05-09 | $48.73M derived: sum of 2 quarters · filed 2018-03-01 | $71.63M derived: sum of 3 quarters · filed 2018-03-01 | $94.82M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2015-12-31 | $23.57M derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-01 | $46.47M derived: sum of 2 quarters · filed 2018-03-01 | $69.66M derived: sum of 3 quarters · filed 2018-03-01 | $89.06M 10-K · filed 2018-03-01 | $89.20M 10-K · filed 2016-03-09 | |||
| 2015-09-30 | $22.90M 10-Q/A · filed 2017-01-20 | $46.09M derived: sum of 2 quarters · filed 2017-01-23 | $65.50M 10-Q/A · filed 2017-01-20 | $65.64M 10-Q · filed 2015-11-09 | $83.56M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-06-30 | $23.19M 10-Q/A · filed 2017-01-23 | $23.34M 10-Q · filed 2015-08-07 | $42.60M 10-Q/A · filed 2017-01-23 | $42.74M 10-Q · filed 2015-08-07 | $60.66M derived: sum of 3 quarters · filed 2017-03-16 | $78.10M derived: sum of 4 quarters · filed 2017-03-16 | ||
| 2015-03-31 | $19.40M 10-Q/A · filed 2017-01-20 | $19.40M 10-Q · filed 2015-05-06 | $37.46M derived: sum of 2 quarters · filed 2017-03-16 | $54.91M derived: sum of 3 quarters · filed 2017-03-16 | $74.49M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | $18.06M derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-16 | $35.50M derived: sum of 2 quarters · filed 2017-03-16 | $55.08M derived: sum of 3 quarters · filed 2017-03-16 | $72.61M 10-K · filed 2017-03-16 | $72.47M 10-K · filed 2015-03-12 | |||
| 2014-09-30 | $17.45M 10-Q/A · filed 2017-01-20 | $17.34M 10-Q · filed 2014-11-12 | $37.03M derived: sum of 2 quarters · filed 2017-01-20 | $54.55M 10-Q/A · filed 2017-01-20 | $54.45M 10-Q · filed 2014-11-12 | $69.78M derived: sum of 4 quarters · filed 2017-01-20 | ||
| 2014-06-30 | $19.58M 10-Q · filed 2015-08-07 | $37.11M 10-Q · filed 2015-08-07 | $52.33M derived: sum of 3 quarters · filed 2017-01-20 | $66.95M derived: sum of 4 quarters · filed 2017-01-20 | ||||
| 2014-03-31 | $17.53M 10-Q · filed 2015-05-06 | $32.75M derived: sum of 2 quarters · filed 2017-01-20 | $47.37M derived: sum of 3 quarters · filed 2017-01-20 | $59.59M derived: sum of 4 quarters · filed 2017-01-20 | ||||
| 2013-12-31 | $15.22M derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-01-20 | $29.84M derived: sum of 2 quarters · filed 2017-01-20 | $42.06M derived: sum of 3 quarters · filed 2017-01-20 | $55.59M 10-K/A · filed 2017-01-20 | ||||
| 2013-09-30 | $14.62M 10-Q · filed 2014-11-12 | $26.83M derived: sum of 2 quarters · filed 2014-11-12 | $40.37M 10-Q · filed 2014-11-12 | $49.05M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-06-30 | $12.21M 10-Q · filed 2014-08-12 | $25.75M 10-Q · filed 2014-08-12 | $34.43M derived: sum of 3 quarters · filed 2015-03-12 | $38.50M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-03-31 | $13.53M 10-Q · filed 2014-05-13 | $22.21M derived: sum of 2 quarters · filed 2015-03-12 | $26.29M derived: sum of 3 quarters · filed 2015-03-12 | $30.93M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2012-12-31 | $8.68M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $12.76M derived: sum of 2 quarters · filed 2015-03-12 | $17.40M derived: sum of 3 quarters · filed 2015-03-12 | $20.13M 10-K · filed 2015-03-12 | ||||
| 2012-09-30 | $4.08M 10-Q · filed 2013-11-13 | $8.72M derived: sum of 2 quarters · filed 2013-11-13 | $11.45M 10-Q · filed 2013-11-13 | $14.23M derived: sum of 4 quarters · filed 2014-03-21 | ||||
| 2012-06-30 | $4.64M 10-Q · filed 2013-08-14 | $7.37M 10-Q · filed 2013-08-14 | $10.16M derived: sum of 3 quarters · filed 2014-03-21 | $11.66M derived: sum of 4 quarters · filed 2014-03-21 | ||||
| 2012-03-31 | $2.73M 10-Q · filed 2013-05-15 | $5.51M derived: sum of 2 quarters · filed 2014-03-21 | $7.01M derived: sum of 3 quarters · filed 2014-03-21 | $8.91M derived: sum of 4 quarters · filed 2014-03-21 | ||||
| 2011-12-31 | $2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | $4.29M derived: sum of 2 quarters · filed 2014-03-21 | $6.18M derived: sum of 3 quarters · filed 2014-03-21 | $7.93M 10-K · filed 2014-03-21 | ||||
| 2011-09-30 | $1.50M 10-Q · filed 2012-11-02 | $3.40M derived: sum of 2 quarters · filed 2012-11-02 | $5.14M 10-Q · filed 2012-11-02 | |||||
| 2011-06-30 | $1.90M 10-Q · filed 2012-08-13 | $3.64M 10-Q · filed 2012-08-13 | ||||||
| 2010-12-31 | $5.08M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |